Korea Quality Re-Rating Watch Nov 9: Hanmi Pharma & Dongkuk Lead

KOSPI breadth mildly negative as batteries sold off sharply; meta screener flags Hanmi Pharma, Dongkuk Pharm and Nanoscale on earnings+flow overlap.

— Recommendations 0

Macro Dashboard

Today’s regime verdict is blocked — the ETF creation proxy feed is stale, preventing a formal KR/US label. Available partial data as of Nov 9:

IndicatorLevelTrend (5 obs)
KR 3Y Bond3.61%–10 bps (Nov 6)
KR 10Y Bond3.85%–15 bps (Nov 6)
US 2Y4.46%–15 bps (Nov 5)
US 10Y4.84%–14 bps (Nov 5)
WTI$99.64–$5.61 (Nov 3)
USD Index102.3+0.42 (Nov 6)
USD/KRWStaleLast observed Oct 30
KOSPI / KOSDAQNot availableNo index close in today’s feed

Regime: KR = UNKNOWN / US = UNKNOWN. Both rate curves stepped lower; HY OAS widened +22 bps. USD firm. No regime stance issued pending data refresh.


Market Wrap

Source: KR Market Snapshot, Nov 9. No full close briefing available; same-day DB used.

Korea’s market closed in soft territory. Of 2,599 listed names, 1,076 advanced and 1,274 declined — a slightly negative breadth count — but the average price change was +0.19%, signaling that gains concentrated in a handful of larger names masked broader selling.

Battery and EV complex under coordinated pressure. The session’s loudest signal came from the battery chain. Samsung SDI (006400.KS) dropped –11.32% with both foreign and institutional investors selling simultaneously. LG Energy Solution (373220.KS) fell –5.78%, Eco Pro BM (247540.KQ) –8.66%, and Eco Pro (086520.KS) –8.46%. This is a cross-sector flush, not random noise, and aligns with global EV demand softness while WTI holds near $100.

Pharma and biotech diverged. SK Bioscience (302440.KS) rose +5.21% on foreign buying. Samsung Biologics (207940.KS) edged down –0.40% but drew net institutional accumulation — a stabilizing pattern worth watching. The sector is bifurcated: CDMO and vaccine platforms attracting inflows, legacy names under pressure.

IT services showed selective strength. LG CNS (064400.KS) gained +4.32% with two-sided institutional and foreign buying — genuine shared conviction, not retail momentum. NAVER (035420.KS) slipped –1.63% but institutions were net buyers, pointing to quiet accumulation into weakness.

Airlines flagged by consensus upgrades. Jeju Air (089590.KS) and Jin Air (272450.KS) both held their prices while sell-side analysts revised estimates higher — a setup where the market has not yet caught up to improving fundamentals.

Cosmetics sold off broadly. Cosmax (192820.KS) –5.30% and Cosméka Korea (241710.KS) –15.09% saw coordinated foreign and institutional selling. The K-beauty complex faces a rough session on cross-border demand concerns.

Overall character: selective rotation. Capital moved away from batteries and cosmetics toward pharma CDMOs and IT services. Breadth was mildly negative, but several quality names are being quietly accumulated beneath the surface.


Today’s Quality Re-Rating Candidates

Source: KR Meta Screener, Nov 9. The PEAD-only intersection found no 2+ screener overlaps today; candidates below are ranked by the Meta Screener’s composite weighted score, which applies historically calibrated weights: Consensus Up Revision (2.20×), RS80 Leadership (1.33×), financial factor screeners (0.58× each).

RankTickerNameMeta ScoreScreener FamiliesEvidence FamiliesKey Signal
1128940.KSHanmi Pharmaceutical55.4Consensus Up + Cycle + Smart Money Earnings + Smart Money Quality5Margin +2.2pp; foreign+institutional absorbed ₩80.7bn in 5d
2121600.KQNanoscale Materials30.5Consensus Up + Cycle3Consensus z +0.65; treasury share disposal filed Nov 6
3086450.KSDongkuk Pharmaceutical67.2Quality Compounder + Cycle + PEAD + Quiet Accum5ROE 9.9%; OP YoY +20.1%; retail sold, smart money absorbed
4002790.KSAmorepacific Holdings30.7RS80 + Quiet Accum + Kiwoom Surface5RS80 Focus Candidate; pivot gap +4.6%; short interest 9.6%
5089590.KSJeju Air23.3Consensus Up3Consensus z +5.68 (highest in today’s table); IR held Nov 3
6272450.KSJin Air19.6Consensus Up + Kiwoom3Consensus z +0.58; two IR catalysts filed Nov 6
7383800.KSLX Holdings17.0Consensus Up2Consensus z +3.84; prelim earnings filed Nov 4
8006730.KSSeobu T&D13.5Consensus Up + Kiwoom3Foreign rank #324; institutional rank #76; ownership 16.7%

Top 3 in Detail

1. Hanmi Pharmaceutical (128940.KS) Korea’s leading innovative pharma company, with biologics in diabetes/obesity, oncology, and rare diseases. It hits four screener families: Consensus Up, Cycle Rerating, Smart Money Earnings, and Smart Money Quality. Retail sellers offloaded approximately ₩64.5bn over the measurement period; foreign and quality-institutional buyers absorbed that supply — a classic divergence between weaker and stronger hands. Operating margin expanded +2.2pp. DART shows an active IR calendar and a confirmed licensing deal for LAGLA (Fabry disease treatment) filed Oct 30. Next check: sell-side consensus revision size, LAGLA deal economics, and whether absorption holds this week.

Why ranked above Dongkuk despite lower raw score: the Consensus Up family carries a 2.20× historical weight, well above the 0.58× applied to financial factor screeners. Hanmi’s estimate revision signal has stronger demonstrated forward-return lift in back-testing than a pure fundamental quality stack.

2. Nanoscale Materials (121600.KQ) Specialty materials supplier for semiconductor and display manufacturing. It appears in both Cycle Rerating and Consensus Up. The treasury share disposal filed Nov 6 is a capital allocation signal that often precedes positive management guidance. The consensus z-score is modest (+0.65) but directionally positive. Next check: disposal structure (employee compensation vs. open-market sale), customer concentration in HBM or CXL-related substrate demand, and whether the cycle rerating is a leading or lagging read.

3. Dongkuk Pharmaceutical (086450.KS) Domestic mid-cap pharma with stable consumer health and specialty drug divisions. The broadest fundamental case in today’s list: Quality Compounder, Cycle Rerating, PEAD, and Quiet Accumulation all trigger together. ROE 9.9%, OP YoY +20.1%, retail exit absorbed by institutional buyers. The PEAD screener places it in Tier C with a 52-week gap of 21.9% and price above MA50 — drift space remains open. Note: PEAD financial data is 242 days old (annual filing), so the most recent quarterly print needs independent verification. Next check: Q3 2026 quarterly results, which product line is driving OP acceleration, and whether the quiet accumulation pattern precedes a disclosed catalyst.


All names above are screener candidates flagged for further research — not buy or sell recommendations. Verify DART filings at source before acting on any signal.

Built with Hugo
Theme Stack designed by Jimmy